Thryv Therapeutics Inc.

Science knows no borders! We're proud to have a team made up of scientists, researchers, and innovators from both sides of the border—and around the world! We stand in support of our colleagues, mentors and the thousands of passionate scientists who dedicate their work to helping, protecting, and finding cures for those in need. The FDA's role is more important than ever as we work toward a common goal: bringing new treatment options to people living with Long QT Syndrome, heart failure, and atrial fibrillation. Together, we are advancing innovation in cardiovascular health. 💚 #TeamThryv #ClinicalResearch #Biotech #Innovation #LQTS #SGK1

Thryv Therapeutics is looking forward to participating in the 2025 Piper Sandler Virtual Cardio Day on April 1. Our leadership team will sit for a fireside chat from 11:30–11:55 a.m. ET, discussing key insights into our latest advancements in SGK1 inhibition for Long QT Syndrome, heart failure, and atrial fibrillation. Read the full press release here: https://loom.ly/RHwDf3A To schedule a meeting: admin@thryvtrx.com #ThryvTherapeutics #CardiovascularResearch #PiperSandler #SGK1 #Biotech

Thank you for joining us this Heart Month as we raised awareness about heart health! We appreciate your engagement and hope you learned something new about Long QT Syndrome, atrial fibrillation, heart failure, and the role of SGK1 in cardiac health. This month, we: ✅ Explored the importance of Heart Month and why heart health matters. ✅ Highlighted three critical heart conditions—LQTS, atrial fibrillation, and heart failure—and their impact on millions worldwide. ✅ Shared how Thryv Therapeutics is striving to advance cardiac care through innovative research on SGK1 inhibition. ✅ Took part in a CPR training session to empower our team with lifesaving skills. 🫀 ✅ Enjoyed some heart-themed treats. ❤️🍪 Heart health awareness doesn’t stop here. Visit our website to explore SGK1 inhibition, patient stories, and the latest updates on our research: www.thryvtrx.com Thank you for supporting the fight against heart disease! ❤️ #HeartMonth2025 #HeartHealth #ThryvTherapeutics #SGK1 #LQTS #AtrialFibrillation #HeartFailure #CPRTraining

Heart failure (HF) affects millions, yet treatment options remain limited—especially for HFpEF (pronounced "heff-peff"), a condition where the heart struggles to relax and fill properly. Two Types of Heart Failure 🔹 HFpEF ("heff-peff") – Stiff heart muscle, impaired relaxation and filling 🔹 HFrEF ("heff-reff") – Weakened heart muscle, reduced pumping ability Why Does HFpEF Remain Such a Challenge? Nearly half of all heart failure patients have HFpEF, and many are also overweight or obese. Risk factors like: ⚠️ Hypertension ⚠️ Obesity ⚠️ Atrial fibrillation (AFib) …share common underlying drivers—insulin resistance, systemic inflammation, and cardiac fibrosis—which contribute to disease progression. The lack of effective treatments for HFpEF represents a large and growing unmet need in cardiology today. The Role of SGK1 in Heart Failure 🧬 Serum and Glucocorticoid Kinase 1 (SGK1) is a key player in the heart’s stress response. Research suggests prolonged SGK1 activity may worsen heart failure. That’s why at Thryv Therapeutics, we’re exploring SGK1 inhibition as a potential treatment for HF. Stay tuned as we continue advancing heart failure research. ❤️ #HeartFailure #HFpEF #HFrEF #SGK1 #CardiovascularHealth #AFib #HeartResearch #HeartMonth

This Week, We’re Talking About Atrial Fibrillation (AFib) 💓 #HeartMonth Atrial fibrillation (AFib) is the most common heart rhythm disorder, affecting over 5 million Americans today, with that number expected to rise to more than 12 million by 2030 (American Heart Association). In Canada, an estimated 200,000 people are living with AFib, and the prevalence increases with age. AFib occurs when the heart’s upper chambers (atria) beat irregularly and out of sync with the lower chambers. This disrupts normal blood flow and significantly increases the risk of stroke, heart failure, and other complications. In fact, AFib is associated with a fivefold increased risk of stroke and doubles the risk of heart-related deaths (National Institutes of Health). 🔍 What Causes Atrial Fibrillation? Several factors can contribute to the development of AFib, including: ✔️ High blood pressure – Can strain and enlarge the heart ✔️ Coronary artery disease – Narrowed arteries reduce blood flow to the heart ✔️ Heart failure – Weakens the heart muscle over time ✔️ Heart valve disease – Can alter blood flow and increase risk ✔️ Sleep apnea – Interruptions in breathing can trigger AFib ✔️ Obesity & diabetes – Increase inflammation and heart strain ✔️ Excessive alcohol or stimulant use – Can disrupt normal heart rhythms ✔️ Aging – The likelihood of AFib increases as we get older ⚠️ Common Symptoms of AFib: AFib symptoms can range from mild to severe—or may not appear at all. These can include: ✔️ Fatigue ✔️ Shortness of breath ✔️ Dizziness or lightheadedness ✔️ Heart palpitations (rapid, fluttering, or pounding heartbeat) ✔️ Chest pain or discomfort ✔️ No symptoms (silent AFib) Because AFib may go unnoticed, many people are diagnosed only after a stroke or serious complication occurs. Early detection and treatment are critical to reducing risks. 💡 Types of Atrial Fibrillation: AFib can be classified into different categories based on duration and recurrence: 🔹 Paroxysmal AFib – Occurs occasionally and may resolve on its own 🔹 Persistent AFib – Lasts more than 7 days and may require treatment 🔹 Long-standing Persistent AFib – Lasts longer than 12 months 🔹 Permanent AFib – Ongoing AFib that is resistant to treatments At Thryv Therapeutics, we’re committed to developing innovative therapies to help those affected by atrial fibrillation and other cardiovascular diseases. Our research focuses on SGK1 inhibitors, a novel approach targeting underlying disease mechanisms to improve outcomes and reduce risks. Stay tuned as we continue the conversation on heart health this Heart Month! ❤️ #AtrialFibrillation #AFibAwareness #HeartHealth #StrokePrevention #ThryvTherapeutics #HeartMonth #SGK1

This Week, We’re Talking About Heart Failure 🫀 #HeartMonth Heart failure (HF) is a serious condition that affects over 6 million Americans and is the leading cause of hospitalization for people over 65. In Canada, approximately 750,000 people are living with heart failure, with 100,000 new cases diagnosed each year. HF occurs when the heart isn’t able to pump blood effectively, leading to symptoms that impact daily life. 🔍 Common Causes of Heart Failure: Several conditions can weaken or stiffen the heart over time, leading to HF, including: ✔️ High blood pressure – Forces the heart to work harder than normal ✔️ Coronary artery disease – Narrowed arteries reduce blood flow to the heart ✔️ Heart attack – Can damage the heart muscle permanently ✔️ Diabetes – Increases the risk of heart disease and HF ✔️ Obesity – Places extra strain on the heart ✔️ Irregular heart rhythms (arrhythmias) – Affect the heart’s ability to pump effectively 💡 The Two Main Types of Heart Failure: 🔹 HFrEF (Heart Failure with Reduced Ejection Fraction): The heart muscle is weakened and struggles to pump blood efficiently, leading to symptoms like swelling, fatigue, and shortness of breath. 🔹 HFpEF (Heart Failure with Preserved Ejection Fraction): The heart’s pumping ability is preserved, but the muscle is stiff and doesn’t fill properly, causing similar symptoms. ⚠️ Common Symptoms of Heart Failure: ✔️ Shortness of breath, especially during activity or while lying down ✔️ Fatigue and weakness ✔️ Swelling in the legs, ankles, or abdomen ✔️ Rapid or irregular heartbeat ✔️ Persistent cough or wheezing with white or pink mucus ✔️ Sudden weight gain from fluid retention Heart failure is a progressive condition, but with early diagnosis, lifestyle changes, and advancing research, patients can manage their symptoms and improve their quality of life. At Thryv Therapeutics, we’re committed to developing innovative therapies to help those affected by heart failure and other cardiovascular diseases. Stay tuned as we continue the conversation on heart health this Heart Month. ❤️ #HeartMonth #HeartFailure #HFrEF #HFpEF #CardiovascularHealth #HeartHealth #SGK1 #ThryvTherapeutics

As we wrap up the week, we're highlighting Long QT Syndrome (LQTS)—the inspiration behind Thryv Therapeutics. We’ll explore key aspects of this condition, the role of serum glucocorticoid-regulated kinase 1 (SGK1) and how our work with SGK1 inhibition could make a difference. 🔎 What is Long QT Syndrome (LQTS)? LQTS is a heart rhythm disorder affecting 1 in 2,000 people in the U.S. It prolongs the heart’s electrical reset time, increasing the risk of dangerous arrhythmias. Nearly 50% of individuals have no symptoms, which can delay diagnosis. LQTS is typically detected via ECG or genetic testing, especially with a family history. 🔴 Symptoms may include: 💢 Unexplained fainting 💢 Seizures 💢 Palpitations 🔎 What Causes LQTS? LQTS is a cardiac channelopathy caused by ion channel dysfunction, mainly affecting potassium (K+) or sodium (Na+) channels. These channels regulate the heart’s electrical activity, and genetic mutations can disrupt their function, leading to prolonged QT intervals and life-threatening arrhythmias. 🔎 Managing LQTS There are no approved medications for LQTS that shorten the QT interval. Since congenital LQTS cannot be prevented, risk management is essential. Treatment options include: 🩺 Lifestyle modification 💊 Beta-blocker therapy ⚡ Implantable cardioverter-defibrillator (ICD) for high-risk patients 🧠 The Mental Health Impact LQTS brings uncertainty, leading to anxiety, depression, and PTSD, especially after cardiac events or ICD shocks. Daily life is affected by activity restrictions, adding to the emotional and physical burden. 📖 Learn more in The SADS Foundation Voice of the Patient Report: https://loom.ly/ajyGRU8 🔎 SGK1’s Role & Our Work at Thryv SGK1 is activated under stress and plays a key role in ion channel regulation. One of our scientific founders, Dr. Saumya Das, and his colleagues hypothesized that blocking SGK1 could help normalize electrical activity and reduce the risk of arrhythmias. At Thryv Therapeutics, we’re developing an SKG1 inhibitor that has been granted FDA Orphan Drug Designation for congenital LQTS. Our Wave I proof-of-efficacy study validated its potential, supporting pivotal trials in 2025. 💡 Learn more about our work at www.thryvtrx.com #HeartMonth #LQTS #LongQTSyndrome #SGK1 #ThryvTherapeutics #OrphanDisease #Cardiology

❤️ CPR: A Lifesaving Skill for Sudden Cardiac Arrest ❤️ Looking back on our CPR training session with CPR Montreal in 2023! 📸 When the heart stops beating, every second counts. CPR (cardiopulmonary resuscitation) is the most critical action in a cardiac emergency—it can double or even triple survival rates if performed immediately. For individuals with Long QT Syndrome (LQTS) and other heart conditions, sudden cardiac arrest can strike without warning. The American Heart Association highlights that electrical abnormalities like LQTS may cause sudden cardiac arrest, even in young people. That’s why knowing CPR can save a life. 💡 Learn CPR. Be prepared. Save a life. Have you taken a CPR course? Share your experience below! ⬇️ #CPRSavesLives #HeartHealth #LQTSAwareness #HeartMonth

Understanding cardiovascular health starts with knowing the key terms. This #HeartMonth, we’re breaking down some important concepts to empower you with the knowledge to protect your heart. Swipe to learn more! ⬅️📖 Knowledge is power – Follow us throughout #HeartMonth for more insights into cardiac health. #HeartGlossary #HeartHealthEducation #ThryvTherapeutics #HeartMonth2025

Did you know? 🫀 Cardiovascular diseases (CVDs) are the leading cause of death worldwide, accounting for approximately 19.91 million global deaths in 2021 according to the American Heart Association (AHA). While medical advances have helped more people live longer with cardiovascular diseases, many of the risk factors which lead to these diseases, including high blood pressure and obesity, continue to grow at alarming rates. 💡 Many CVDs are preventable through lifestyle changes, early detection, and effective management. Why awareness matters: ✅ Recognizing early warning signs can lead to timely intervention and save lives. ✅ Education empowers individuals to make heart-healthy choices and reduce risk factors. ✅ Advocacy fuels research and innovation, driving new treatments and better care options. ✅ Early diagnosis improves outcomes, especially for inherited conditions like Long QT Syndrome (LQTS). ✅ Increased awareness leads to better screening, helping those at risk take action before it’s too late. At Thryv Therapeutics, we’re committed to raising awareness, supporting education, and advancing treatments for Long QT Syndrome (LQTS), heart failure, and atrial fibrillation. This #HeartMonth, let’s shine a light on the global fight against heart disease. ❤️🔬 Coming next: A Heart Health Glossary! Stay tuned as we break down key terms related to cardiovascular health. #HeartHealth #CardiovascularResearch #LQTS #CardiacCare #SGK1 #HeartMonth2025 #ThryvTherapeutics